Just wondering, anyone else find it interesting that Edison placed a target
of $6-8M for milestone payment from GSK for IMP731, but none for Novartis
with its IMP701 licence.....I note, lag-525 starting ph2......For mine, I thought
they would more likely to discharge a MP before GSK......
Bear in mind, Immutep is a client of Edison...
Edisonreport..., page-3
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.020(6.06%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.3¢ | 30.5¢ | $1.905M | 6.153M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 13147 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 101130 | 2 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
